RUA Life Sciences has reported its interim results for the six-months to September 22, detailing progress across each of its four business units. The company has delivered strong revenue growth of 56%, while maintaining tight control on its cost base, such that the end of period cash balance was £2.5m vs £3.0m at March 2022, ahead of an expected R&D Tax Credit. Discussions with the FDA on the vascular graft devices have progressed and RUA sees the requirements of the human clinical study much re ....
13 Dec 2022
Cenkos: RUA Life Sciences Plc -- Group progress
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: RUA Life Sciences Plc -- Group progress
RUA Life Sciences Plc (RUA:LON) | 11.0 -0.1 (-4.3%) | Mkt Cap: 6.83m
- Published:
13 Dec 2022 -
Author:
Chris Donnellan -
Pages:
8
RUA Life Sciences has reported its interim results for the six-months to September 22, detailing progress across each of its four business units. The company has delivered strong revenue growth of 56%, while maintaining tight control on its cost base, such that the end of period cash balance was £2.5m vs £3.0m at March 2022, ahead of an expected R&D Tax Credit. Discussions with the FDA on the vascular graft devices have progressed and RUA sees the requirements of the human clinical study much re ....